Source:http://linkedlifedata.com/resource/pubmed/id/18987435
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2008-11-21
|
pubmed:abstractText |
Glucagon-like peptide-1 (GLP-1) induces pancreatic insulin secretion via the cAMP-dependent protein kinase (PKA) pathway. However, the GLP-1 concentration used in the previous in vitro experiments was far from the in vivo concentrations. Alteration of plasma GLP-1 concentration at pM order lowers blood glucose concentration. In this study, we examined the GLP-1 action mechanism at a physiological concentration on insulin secretion. A high concentration of GLP-1 (10 nM) stimulated intracellular cAMP accumulation and insulin secretion was significantly inhibited by KT5720, a selective inhibitor of PKA. Low GLP-1 concentrations (1 pM) also increased insulin secretion without significant accumulation of intracellular cAMP, and KT5720 did not affect insulin secretion. Insulin secretion stimulated by 1 pM GLP-1 was reduced by inhibitors of calcium action, including verapamil, dantrolene, and BAPTA. Thus, we concluded that relatively low GLP-1 concentrations-comparable to in vivo blood concentrations-promoted insulin secretion independent of the cAMP-PKA pathway. This effect was dependent on intracellular Ca2+ concentration. The results of the present study may further the understanding of the dose-dependent response of GLP-1 signal transducing pathways and the complicated mechanism of insulin secretion. Studies of GLP-1 at physiologic concentrations may lead to new developments in studies of pancreatic beta-cell function.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Calcium,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Chelating Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP-Dependent Protein Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Glucagon-Like Peptide 1,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1347-8613
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
108
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
274-9
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:18987435-Animals,
pubmed-meshheading:18987435-Calcium,
pubmed-meshheading:18987435-Calcium Channel Blockers,
pubmed-meshheading:18987435-Cell Line,
pubmed-meshheading:18987435-Chelating Agents,
pubmed-meshheading:18987435-Cyclic AMP,
pubmed-meshheading:18987435-Cyclic AMP-Dependent Protein Kinases,
pubmed-meshheading:18987435-Glucagon-Like Peptide 1,
pubmed-meshheading:18987435-Humans,
pubmed-meshheading:18987435-Insulin,
pubmed-meshheading:18987435-Insulin-Secreting Cells,
pubmed-meshheading:18987435-Protein Kinase Inhibitors,
pubmed-meshheading:18987435-Signal Transduction,
pubmed-meshheading:18987435-Time Factors,
pubmed-meshheading:18987435-Up-Regulation
|
pubmed:year |
2008
|
pubmed:articleTitle |
Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway.
|
pubmed:affiliation |
Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School, Kurashiki, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|